Your session is about to expire
← Back to Search
JAB-3312 Combination Therapy for Advanced Cancer
Study Summary
This trial is testing a new drug to see if it is safe and tolerated in adults with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a history of a different type of cancer than the one being studied.You have a history of lung disease or inflammation.You have a serious medical condition that is not under control.Your organs (heart, lungs, liver, kidneys) are working properly.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: JAB-3312+Sotorasib dose escalation
- Group 2: JAB-3312+Pembrolizumab dose escalation
- Group 3: JAB-3312+ Binimetinib dose escalation
- Group 4: JAB-3312+Pembrolizumab dose expansion
- Group 5: JAB-3312+Binimetinib dose expansion
- Group 6: JAB-3312+ Osimertinib dose escalation
- Group 7: JAB-3312+ Sotorasib dose expansion
- Group 8: JAB-3312+ Osimertinib dose expansion
Frequently Asked Questions
Are there any vacancies available in this research program for participants?
"That is correct. According to clinicaltrials.gov, the medical trial which was initially published on March 23rd 2021 is actively searching for eligible participants; 200 individuals are needed from 15 different sites."
For what medical conditions is JAB-3312 typically prescribed?
"JAB-3312 is primarily used to fight malignant neoplasms, but it can also be utilized in cases of unresectable melanoma and microsatellite instability high. Additionally, this medication may have applications for those who need treatment after chemotherapy."
What is the current size of enrolment for this clinical trial?
"Affirmative. As indicated in the trial records hosted on clinicaltrials.gov, this medical research is actively seeking participants; it was initially appended to the site on March 23rd 2021 and last edited on October 26th 2022. 200 people need to be recruited from 15 different healthcare facilities for this study to move forward."
Are there numerous venues conducting this clinical research in North America?
"This clinical trial is running concurrently at 15 different sites, based in metropolitan areas such as Rochester, Los Angeles and New york. To make the most of your time if you choose to participate, consider looking for a location that is closest to where you live."
Could you elaborate on what other research has been conducted regarding JAB-3312?
"At the City of Hope, investigations into JAB-3312 began a decade ago and have yielded 290 completed trials. As it stands, 1,011 ongoing studies are being conducted across Rochester Minnesota alone."
Share this study with friends
Copy Link
Messenger